Developments in pulmonary arterial hypertension–targeted therapy for chronic thromboembolic pulmonary hypertension

References

• Hoeper MM, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D42-50
   PubMed Web of Science ®Google Scholar
• Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D34-41
   PubMed Web of Science ®Google Scholar
• Wagenvoort CA, Wagenvoort N. Primary Pulmonary Hypertension: A Pathologic Study of the Lung Vessels in 156 Clinically Diagnosed Cases. Circulation 1970;42(6):1163-84
   Web of Science ®Google Scholar
• Bernard J, Yi ES. Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. Hum Pathol 2007;38(6):871-7
   PubMed Web of Science ®Google Scholar
• Jenkins DP, Madani M, Mayer E, et al. Surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2013;41(3):735-42
   PubMed Web of Science ®Google Scholar
• Mayer E, Jenkins D, Lindner J, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg 2011;141(3):702-10
   PubMed Web of Science ®Google Scholar
• Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008;177(10):1122-7
   PubMed Web of Science ®Google Scholar
• Aldred MA, Vijayakrishnan J, James V, et al. BMPR2 gene rearrangements account for a significant proportion of mutations in familial and idiopathic pulmonary arterial hypertension. Hum Mutat 2006;27(2):212-13
   PubMed Web of Science ®Google Scholar
• Pengo V, Lensing AW, Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med 2004;350(22):2257-64
   PubMed Web of Science ®Google Scholar
• Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 2010;126(1):51-6
   PubMed Web of Science ®Google Scholar
• Marti D, Gomez V, Escobar C, et al. [Incidence of symptomatic and asymptomatic chronic thromboembolic pulmonary hypertension]. Arch Bronconeumol 2010;46(12):628-33
   PubMed Web of Science ®Google Scholar
• Guerin L, Couturaud F, Parent F, et al. Prevalence of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Prevalence of CTEPH after pulmonary embolism. Thromb Haemost 2014;112(3):598-605
   PubMed Web of Science ®Google Scholar
• Pepke-Zaba J, Delcroix M, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124(18):1973-81
   PubMed Web of Science ®Google Scholar
• Marsh JJ, Chiles PG, Liang NC, Morris TA. Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure. Thromb Res 2013;132(6):729-34
   PubMed Web of Science ®Google Scholar
• Zabini D, Heinemann A, Foris V, et al. Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients. Eur Respir J 2014;44(4):951-62
   PubMed Web of Science ®Google Scholar
• Wynants M, Quarck R, Ronisz A, et al. Effects of C-reactive protein on human pulmonary vascular cells in chronic thromboembolic pulmonary hypertension. Eur Respir J 2012;40(4):886-94
   PubMed Web of Science ®Google Scholar
• Alias S, Redwan B, Panzenbock A, et al. Defective angiogenesis delays thrombus resolution: a potential pathogenetic mechanism underlying chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014;34(4):810-19
   PubMed Web of Science ®Google Scholar
• Quarck R, Wynants M, Verbeken E, et al. Contribution of inflammation and impaired angiogenesis to the pathobiology of chronic thromboembolic pulmonary hypertension. Eur Respir J 2015;46(2):431-43
   PubMed Web of Science ®Google Scholar
• Yi ES, Kim H, Ahn H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162(4 Pt 1):1577-86
   PubMed Web of Science ®Google Scholar
• Moser KM, Bloor CM. Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest 1993;103(3):685-92
   PubMed Web of Science ®Google Scholar
• Azarian R, Wartski M, Collignon MA, et al. Lung perfusion scans and hemodynamics in acute and chronic pulmonary embolism. J Nucl Med 1997;38(6):980-3
   PubMed Web of Science ®Google Scholar
• Mercier O, Tivane A, Dorfmuller P, et al. Piglet model of chronic pulmonary hypertension. Pulm Circ 2013;3(4):908-15
   PubMedGoogle Scholar
• Langer F, Bauer M, Tscholl D, et al. Circulating big endothelin-1: an active role in pulmonary thromboendarterectomy? J Thorac Cardiovasc Surg 2005;130(5):1342-7
   PubMed Web of Science ®Google Scholar
• Bauer M, Wilkens H, Langer F, et al. Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation 2002;105(9):1034-6
   PubMed Web of Science ®Google Scholar
• Reesink HJ, Meijer RC, Lutter R, et al. Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. Circ J 2006;70(8):1058-63
   PubMed Web of Science ®Google Scholar
• Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 2006;130(3):841-6
   PubMed Web of Science ®Google Scholar
• Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008;21(5):824-32
   PubMed Web of Science ®Google Scholar
• Suntharalingam J, Hughes RJ, Goldsmith K, et al. Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH). Vascul Pharmacol 2007;46(6):449-55
   PubMed Web of Science ®Google Scholar
• Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008;76(2):154-9
   PubMed Web of Science ®Google Scholar
• Kramm T, Eberle B, Krummenauer F, et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003;76(3):711-18
   PubMed Web of Science ®Google Scholar
• Kramm T, Eberle B, Guth S, Mayer E. Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy. Eur J Cardiothorac Surg 2005;28(6):882-8
   PubMed Web of Science ®Google Scholar
• Richter MJ, Ghofrani HA, Voswinckel R, et al. Acute hemodynamic effects of nebulized iloprost via the I-neb Adaptive Aerosol Delivery system in pulmonary hypertension. Pulm Circ 2015;5(1):162-70
   PubMedGoogle Scholar
• Bonderman D, Nowotny R, Skoro-Sajer N, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128(4):2599-603
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36(4):792-9
   PubMed Web of Science ®Google Scholar
• Galie N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D60-72
   PubMed Web of Science ®Google Scholar
• McLaughlin V, Genthner D, Panella M, et al. Compassionate Use of Continuous Prostacyclin in the Management of Secondary Pulmonary Hypertension: A Case Series. Ann Intern Med 1999;130(9):740-3
   PubMed Web of Science ®Google Scholar
• Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998;80(2):151-5
   PubMed Web of Science ®Google Scholar
• Scelsi L, Ghio S, Campana C, et al. Epoprostenol in chronic thromboembolic pulmonary hypertension with distal lesions. Ital Heart J 2004;5(8):618-23
   PubMedGoogle Scholar
• Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007;26(4):357-62
   PubMed Web of Science ®Google Scholar
• Ono F, Nagaya N, Okumura H, et al. Effect of orally active prostacyclin analogue on survival in patients with chronic thromboembolic pulmonary hypertension without major vessel obstruction. Chest 2003;123(5):1583-8
   PubMed Web of Science ®Google Scholar
• Vizza CD, Badagliacca R, Sciomer S, et al. Mid-term efficacy of beraprost, an oral prostacyclin analog, in the treatment of distal CTEPH: a case control study. Cardiology 2006;106(3):168-73
   PubMed Web of Science ®Google Scholar
• Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest 2006;129(6):1636-43
   PubMed Web of Science ®Google Scholar
• Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007;5(3):483-9
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003;167(8):1139-41
   PubMed Web of Science ®Google Scholar
• Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007;30(5):922-7
   PubMed Web of Science ®Google Scholar
• Hughes R, George P, Parameshwar J, et al. Bosentan in inoperable chronic thromboembolic pulmonary hypertension. Thorax 2005;60(8):707
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128(4):2363-7
   PubMed Web of Science ®Google Scholar
• Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28(1):138-43
   PubMed Web of Science ®Google Scholar
• Hirashiki A, Adachi S, Nakano Y, et al. Cardiopulmonary exercise testing to evaluate the exercise capacity of patients with inoperable chronic thromboembolic pulmonary hypertension: an endothelin receptor antagonist improves the peak PETCO2. Life Sci 2014;118(2):397-403
   PubMed Web of Science ®Google Scholar
• Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33(4):785-92
   PubMed Web of Science ®Google Scholar
• Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347(5):322-9
   PubMed Web of Science ®Google Scholar
• Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008;134(2):229-36
   PubMed Web of Science ®Google Scholar
• Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353(20):2148-57
   PubMed Web of Science ®Google Scholar
• Jais X, D’Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (bosentan effects in inoperable forms of chronic thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52(25):2127-34
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, D’Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013;369(4):319-29
   PubMed Web of Science ®Google Scholar
• Simonneau G, D’Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015;45(5):1293-302
   PubMed Web of Science ®Google Scholar
• Early access study (EAS) of riociguat in patients with chronic thromboembolic pulmonary hypertension (CTEPH): Exploratory interim safety assessment (ATS Journals) 2015. Available from: www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2015.191.1_MeetingAbstracts.A4840
   Google Scholar
• Adempas 0.5 mg film-coated tablets - Summary of Product Characteristics (SPC) - (eMC) of first authorisation: 27 March 2014. Available from: www.medicines.org.uk/emc/medicine/28739 [Last accessed 30 June 2015]
   Google Scholar
• D’Armini AM, Ghofrani HA, Kim NH, et al. Use of responder threshold criteria to evaluate the response to treatment in the phase III CHEST-1 study. J Heart Lung Transplant 2015;34(3):348-55
   PubMed Web of Science ®Google Scholar
• Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003;123(2):338-43
   PubMed Web of Science ®Google Scholar
• Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23(4):595-600
   PubMed Web of Science ®Google Scholar
• Reesink HJ, Surie S, Kloek JJ, et al. Bosentan as a bridge to pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2010;139(1):85-91
   PubMed Web of Science ®Google Scholar
• Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009;120(13):1248-54
   PubMed Web of Science ®Google Scholar
• Nagendran J, Archer SL, Soliman D, et al. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation 2007;116(3):238-48
   PubMed Web of Science ®Google Scholar
• Claessen G, La Gerche A, Wielandts JY, et al. Exercise pathophysiology and sildenafil effects in chronic thromboembolic pulmonary hypertension. Heart 2015;101(8):637-44
   PubMed Web of Science ®Google Scholar
• Pacher P, Nagayama T, Mukhopadhyay P, et al. Measurement of cardiac function using pressure–volume conductance catheter technique in mice and rats. Nat Protoc 2008;3(9):1422-34
   PubMed Web of Science ®Google Scholar
• Nagendran J, Sutendra G, Paterson I, et al. Endothelin axis is upregulated in human and rat right ventricular hypertrophy. Circ Res 2013;112(2):347-54
   PubMedGoogle Scholar
• Seyfarth HJ, Hammerschmidt S, Pankau H, et al. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007;74(3):287-92
   PubMed Web of Science ®Google Scholar
• Surie S, Reesink HJ, Marcus JT, et al. Bosentan treatment is associated with improvement of right ventricular function and remodeling in chronic thromboembolic pulmonary hypertension. Clin Cardiol 2013;36(11):698-703
   PubMed Web of Science ®Google Scholar
• Marra AM, Egenlauf B, Ehlken N, et al. Change of right heart size and function by long-term therapy with riociguat in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Int J Cardiol 2015;195:19-26
   PubMed Web of Science ®Google Scholar
• MacKenzie Ross RV, Toshner MR, Soon E, et al. Decreased time constant of the pulmonary circulation in chronic thromboembolic pulmonary hypertension. Am J Physiol Heart Circ Physiol 2013;305(2):H259-64
   PubMedGoogle Scholar
• Tedford RJ. Determinants of right ventricular afterload (2013 Grover Conference series). Pulm Circ 2014;4(2):211-19
   PubMedGoogle Scholar
• de Perrot M, McRae K, Shargall Y, et al. Early postoperative pulmonary vascular compliance predicts outcome after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. Chest 2011;140(1):34-41
   PubMed Web of Science ®Google Scholar
• Ghio S, Morsolini M, Corsico A, et al. Pulmonary arterial compliance and exercise capacity after pulmonary endarterectomy. Eur Respir J 2014;43(5):1403-9
   PubMed Web of Science ®Google Scholar
• Bonderman D, Martischnig AM, Vonbank K, et al. Right ventricular load at exercise is a cause of persistent exercise limitation in patients with normal resting pulmonary vascular resistance after pulmonary endarterectomy. Chest 2011;139(1):122-7
   PubMed Web of Science ®Google Scholar
• Claessen G, La Gerche A, Dymarkowski S, et al. Pulmonary vascular and right ventricular reserve in patients with normalized resting hemodynamics after pulmonary endarterectomy. J Am Heart Assoc 2015;4(3):e001602
   PubMed Web of Science ®Google Scholar
• McCabe C, White PA, Hoole SP, et al. Right ventricular dysfunction in chronic thromboembolic obstruction of the pulmonary artery: a pressure-volume study using the conductance catheter. J Appl Physiol 2014;116(4):355-63
   PubMed Web of Science ®Google Scholar
• Seyfarth HJ, Halank M, Wilkens H, et al. Standard PAH therapy improves long term survival in CTEPH patients. Clin Res Cardiol 2010;99(9):553-6
   PubMed Web of Science ®Google Scholar
• Marini C, Formichi B, Bauleo C, et al. Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension. Intern Emerg Med 2013;8(4):307-16
   PubMed Web of Science ®Google Scholar
• Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest 1982;81(2):151-8
   PubMed Web of Science ®Google Scholar
• Saouti N, de Man F, Westerhof N, et al. Predictors of mortality in inoperable chronic thromboembolic pulmonary hypertension. Respir Med 2009;103(7):1013-19
   PubMed Web of Science ®Google Scholar
• Nishimura R, Tanabe N, Sugiura T, et al. Improved survival in medically treated chronic thromboembolic pulmonary hypertension. Circ J 2013;77(8):2110-17
   PubMed Web of Science ®Google Scholar
• Yoshimi S, Tanabe N, Masuda M, et al. Survival and quality of life for patients with peripheral type chronic thromboembolic pulmonary hypertension. Circ J 2008;72(6):958-65
   PubMed Web of Science ®Google Scholar
• Inami T, Kataoka M, Ando M, et al. A new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies; pulmonary endarterectomy and percutaneous transluminal pulmonary angioplasty. PLoS One 2014;9(4):e94587
   PubMedGoogle Scholar
• Wieteska M, Biederman A, Kurzyna M, et al. Outcome of Medically Versus Surgically Treated Patients With Chronic Thromboembolic Pulmonary Hypertension. Clin Appl Thromb Hemost 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Scholzel BE, Post MC, Thijs Plokker HW, Snijder RJ. Clinical worsening during long-term follow-up in inoperable chronic thromboembolic pulmonary hypertension. Lung 2012;190(2):161-7
   PubMed Web of Science ®Google Scholar
• Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D92-9
   PubMed Web of Science ®Google Scholar
• Simonneau G, Delcroix M, Lang I, et al. Long-term outcome of patients with chronic thromboembolic pulmonary hypertension: Results of an international prospective registry comparing operated versus non operated patients. Resp Crit Care Med 2013;A5365-A
   Google Scholar
• Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg 2012;94(1):97-103
   PubMed Web of Science ®Google Scholar
• Thistlethwaite PA, Kemp A, Du L, et al. Outcomes of pulmonary endarterectomy for treatment of extreme thromboembolic pulmonary hypertension. J Thorac Cardiovasc Surg 2006;131(2):307-13
   PubMed Web of Science ®Google Scholar
• Franco P. Orphan drugs: the regulatory environment. Drug Discov Today 2013;18(3-4):163-72
   PubMed Web of Science ®Google Scholar
• Commissioner oot. Designating an orphan product: Drugs and biological products [WebContent]. office of the commissioner; 2015. Available from: www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/HowtoapplyforOrphanProductDesignation/default.htm [Last accessed 12 Aug 2015]
   Google Scholar
• Onakpoya IJ, Spencer EA, Thompson MJ, Heneghan CJ. Effectiveness, safety and costs of orphan drugs: an evidence-based review. BMJ Open 2015;5(6):e007199
   PubMed Web of Science ®Google Scholar
• Sitaxentan (Thelin): worldwide withdrawal from the market Drug Safety Update - GOV.UK 2011. Available from: www.gov.uk/drug-safety-update/sitaxentan-thelin-worldwide-withdrawal-from-the-market [Last accessed 12 Aug 2015]
   Google Scholar